A drug based on the plasma of recovered COVID patients has passed clinical trials

The Covid-globulin drug has passed clinical trials and received a permanent registration certificate from the Russian Ministry of HEALTH. This is reported by Rostec, whose subsidiary holding, Nacimbio, produces the drug. 

“The world's first specific anti-covid immunoglobulin preparation has successfully passed the final two phases of clinical trials, proving its safety and effectiveness,” said Sergey Chemezov, CEO of the state corporation.

"Covid-globulin" contains antibodies to covid-19 , which were obtained from the blood plasma of people who have recovered from the disease. The antibodies that make up the drug can neutralize currently circulating CORONAVIRUS strains.

According to the results of a double-blind, placebo-controlled comparative study, in 7 out of 10 patients who were treated with COVID-globulin as part of complex therapy, there was a decrease in the risk of the disease progressing to a more severe form. The greatest effectiveness of "Covid-globulin" was manifested when used in the early stages of the disease, the state corporation said.

The drug was developed and produced by the research and production association Microgen, which is part of the Nacimbio holding.